Please assess the completion status of the following clinical trial:

Trial Title: Valsartan in Cardiovascular Disease With Renal Dysfunction (The V-CARD) Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria (all required):~* Systolic blood pressure (SBP) \>/= 140 and/or diastolic blood pressure (DBP) \>/= 90 (untreated hypertension cases); or SBP\>/=130 and/or DBP\>/=80 (treated hypertension cases)~* Patients with coronary artery disease (more than 50% stenosis on coronary angiography \[CAG\], coronary computed tomography \[CT\] or coronary magnetic resonance angiography \[MRA\]; coronary spasm; or history of percutaneous coronary intervention \[PCI\]);Unstable angina patient~* Creatinine clearance between 30.0 and 89.9 ml/min~Exclusion Criteria (at least one of following):~* Reduced left ventricular (LV) function (ejection fraction \[EF\] equal to or less than 40%)~* Hyperpotassemia (serum potassium equal to or more than 5.5 mEq/l)~* Rapid progressive glomerular nephritis~* Nephrotic syndrome~* Renal artery stenosis~* Uncontrolled diabetes (HbA1c equal to or more than 9.0%)~* History of allergy to valsartan~* Pregnant women

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Valsartan 40mg (Type: ACTIVE_COMPARATOR): Standard Dose valsartan
- Valsartan 160mg (Type: ACTIVE_COMPARATOR): High Dose valsartan

Based on this trial design, predict the completion outcome and termination type (if applicable).